ResearcherCentre National de la Recherche ScientifiqueNo recent work listed
Benjamin Bian
Matched on ORCID iD 0000-0001-8691-5292; OpenAlex author ID A5023667997. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers
Papers 7
- Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2018.1561120↗
- Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). Co-author DOI 10.3389/fonc.2019.00475↗
- Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Co-author DOI 10.1038/s41467-018-04383-6↗
- E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based t… First author DOI 10.1038/s41598-018-26613-z↗
- Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
- Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
- A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Juan Iovanna · 7 shared papers, 2016–2019 · strength 0.45
- Paper Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
- Paper Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). DOI 10.3389/fonc.2019.00475↗
- Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
- Nelson Dusetti · 7 shared papers, 2016–2019 · strength 0.45
- Paper Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcin… DOI 10.1080/2162402x.2018.1561120↗
- Paper Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). DOI 10.3389/fonc.2019.00475↗
- Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
- Odile Gayet · 6 shared papers, 2016–2019 · strength 0.36
- Paper Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). DOI 10.3389/fonc.2019.00475↗
- Paper E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but n… DOI 10.1038/s41598-018-26613-z↗
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Véronique Secq · 4 shared papers, 2016–2018 · strength 0.19
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Jean‐Robert Delpéro · 4 shared papers, 2016–2018 · strength 0.19
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Olivıer Turrini · 4 shared papers, 2016–2018 · strength 0.19
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Marc F. Giovannini · 4 shared papers, 2016–2018 · strength 0.19
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Marine Gilabert · 4 shared papers, 2016–2018 · strength 0.19
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Rémy Nicolle · 3 shared papers, 2017–2018 · strength 0.14
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Raul A. Urrutia · 3 shared papers, 2017–2018 · strength 0.14
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Gwen Alyce Lomberk · 3 shared papers, 2017–2018 · strength 0.14
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Pauline Duconseil · 3 shared papers, 2016–2018 · strength 0.14
- Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
- Julie Roques · 2 shared papers, 2017–2019 · strength 0.14
- Paper Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). DOI 10.3389/fonc.2019.00475↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Céline Loncle · 3 shared papers, 2016–2017 · strength 0.13
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
- Mehdi Ouaïssi · 3 shared papers, 2016–2017 · strength 0.13
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
- Flora Poizat · 3 shared papers, 2016–2017 · strength 0.13
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
- Daniele Fanale · 1 shared paper, 2019 · strength 0.09
- Jerome F. Cros · 1 shared paper, 2019 · strength 0.09
- Daniel Olive Directeur · 1 shared paper, 2019 · strength 0.09
- Natalia Anahi Juiz · 1 shared paper, 2019 · strength 0.09
- Antonio Dello Russo · 1 shared paper, 2019 · strength 0.09
- Jean‐Luc Raoul · 2 shared papers, 2017 · strength 0.09
- Paper Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain i… DOI 10.15252/emmm.201606975↗
- Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
- Jonathan Garnier · 2 shared papers, 2016–2017 · strength 0.09
- Sophie Vasseur · 2 shared papers, 2016–2017 · strength 0.09
- Yi Xia · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.